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Abstract
Background—The optimal time for the initiation of antiretroviral therapy for asymptomatic
patients with human immunodeficiency virus (HIV) infection is uncertain.
Methods—We conducted two parallel analyses involving a total of 17,517 asymptomatic
patients with HIV infection in the United States and Canada who received medical care during the
period from 1996 through 2005. None of the patients had undergone previous antiretroviral
therapy. In each group, we stratified the patients according to the CD4+ count (351 to 500 cells
per cubic millimeter or >500 cells per cubic millimeter) at the initiation of antiretroviral therapy.
In each group, we compared the relative risk of death for patients who initiated therapy when the
CD4+ count was above each of the two thresholds of interest (early-therapy group) with that of
patients who deferred therapy until the CD4+ count fell below these thresholds (deferred-therapy
group).
Results—In the first analysis, which involved 8362 patients, 2084 (25%) initiated therapy at a
CD4+ count of 351 to 500 cells per cubic millimeter, and 6278 (75%) deferred therapy. After
adjustment for calendar year, cohort of patients, and demographic and clinical characteristics,
among patients in the deferred-therapy group there was an increase in the risk of death of 69%, as
compared with that in the early-therapy group (relative risk in the deferred-therapy group, 1.69;
95% confidence interval [CI], 1.26 to 2.26; P<0.001). In the second analysis involving 9155
patients, 2220 (24%) initiated therapy at a CD4+ count of more than 500 cells per cubic millimeter
and 6935 (76%) deferred therapy. Among patients in the deferred-therapy group, there was an
increase in the risk of death of 94% (relative risk, 1.94; 95% CI, 1.37 to 2.79; P<0.001).
Conclusions—The early initiation of antiretroviral therapy before the CD4+ count fell below
two prespecified thresholds significantly improved survival, as compared with deferred therapy.
The use of antiretroviral therapy has dramatically reduced disease progression and death
among patients with human immunodeficiency virus (HIV) infection,1,2 but the optimal
time to begin therapy is uncertain.3,4 Current guidelines recommend treatment for
asymptomatic patients who have a CD4+ count of less than 350 cells per cubic millimeter on
the basis of accumulating observational data.5,6 However, these guidelines note the lack of
data from randomized clinical trials regarding the timing of the initiation of antiretroviral
therapy.3,4 Data from randomized trials are limited to an analysis of a subgroup of 477
patients7 from the Strategies for Management of Antiretroviral Therapy (SMART) trial
(ClinicalTrials.gov number, NCT00027352),8 which suggested that deferring antiretroviral
therapy until the CD4+ count fell below 250 cells per cubic millimeter increased the risk of
progression to the acquired immunodeficiency syndrome (AIDS) or death, as compared with
initiation of therapy at a CD4+ count of more than 350 cells per cubic millimeter.7,9
Several observational studies have examined the prognosis for patients who begin
antiretroviral therapy at different CD4+ counts.5,6,10-16 However, these studies do not
address the question of when to start antiretroviral therapy, since they do not have a
comparison group of patients who deferred therapy.17,18 A few studies have compared
patients with similar CD4+ counts who either initiated or deferred antiretroviral therapy,
19-24 but these studies did not have the statistical power and methods18,25,26 to examine
differences in outcomes, particularly among patients with higher CD4+ counts.
Since previous studies have enrolled small numbers of patients and had a relatively short
follow-up,19-24,27 they have required the use of a combined end point of progression to an
AIDS-defining illness or death. However, serious conditions that are not traditionally
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considered to be associated with AIDS have resulted in death and complications in HIV-
infected patients,8,28 and the risk of these conditions is greater than the risk of AIDS among
patients with a CD4+ count of more than 200 cells per cubic millimeter.29-33
Emerging data about the benefits of early antiretroviral treatment, including a better
response to therapy and a preservation of immune function,34-39 suggest that the initiation of
antiretroviral therapy earlier in the course of HIV infection may improve long-term
outcomes. In a recently established collaboration of research groups in the United States and
Canada, we examined all HIV-infected patients with a CD4+ count ranging from 351 to 500
cells per cubic millimeter and all patients with a CD4+ count of more than 500 cells per
cubic millimeter who had received no previous antiretroviral therapy and had no history of
an AIDS-defining illness to determine whether the initiation of antiretroviral therapy at early
stages of HIV infection would be associated with better survival than deferred therapy.
Methods
Study Patients
The data for this study were collected as part of the North American AIDS Cohort
Collaboration on Research and Design (NA-ACCORD) of the International Epidemiological
Databases to Evaluate AIDS project. Details on the collaboration and sites have been
published previously.40 Briefly, the NA-ACCORD consists of 22 research groups,
representing more than 60 cites. The study was approved by local institutional review boards
and used standardized methods of data collection, including routine surveillance of U.S.
national and Canadian provincial death indexes. Each group of investigators submitted data
regarding demographic characteristics, treatment, and clinical, laboratory, and vital status on
enrolled patients.
We conducted parallel analyses on two distinct study groups of patients who received
medical care between January 1996 and December 2005, had not had a previous AIDS-
defining illness (according to 1993 criteria of the Centers for Disease Control and
Prevention41), and had not undergone previous antiretroviral therapy. The patients were
identified from a total of 67,527 patients who underwent screening. For the first analysis, we
identified all patients who had a CD4+ count of 351 to 500 cells per cubic millimeter. For
the second analysis, we identified patients who had a CD4+ count of more than 500 cells per
cubic millimeter.
Study Definitions
Antiretroviral therapy was defined as a regimen containing at least three antiretroviral drugs,
including a protease inhibitor, a nonnucleoside reverse-transcriptase inhibitor, or three
nucleoside reverse-transcriptase inhibitors, including abacavir or tenofovir.
In a study design similar to that of a randomized clinical trial, we compared the rates of
death from any cause in the group that initiated antiretroviral therapy when the CD4+ count
was within one of the two thresholds of interest (early-therapy group) with the rate in the
group that did not initiate antiretroviral therapy until the CD4+ count fell below these
thresholds (deferred-therapy group). Follow-up ended at the month of death, at 1 year after
the date of the last measurement of the CD4+ count, or on December 31, 2005, whichever
occurred first.
Statistical Analysis
The baseline characteristics of patients who initiated antiretroviral therapy early were
compared with those who deferred therapy with the use of Wilcoxon and chi-square tests for
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association. Among the patients in the deferred-therapy group who transitioned to a CD4+
count of either 350 cells or less or 500 cells or less per cubic millimeter, we identified and
characterized the subgroup that initiated antiretroviral therapy.
We used multivariate Cox proportional-hazards models with strata for each cohort of
patients and each baseline calendar year. Baseline was defined as the date of the first
measurement of a CD4+ count either in the range of 351 to 500 or of more than 500 cells per
cubic millimeter. To avoid immortal time bias,42 patients in the early-therapy group
contributed person-time to the deferred-therapy group between baseline and the date of
initiation of antiretroviral therapy. After the initiation of antiretroviral therapy, these patients
contributed all person-time to the early-therapy group in an intention-to-treat approach that
ignored subsequent changes in therapy. In addition to the primary analysis between the
early-therapy group and the deferred-therapy group, adjustment was made for sex, age, and
the CD4+ count at baseline. Data regarding other prognostic factors in patients with HIV
infection (including the HIV RNA level,43 a history injection-drug use,35 the presence or
absence of hepatitis C virus [HCV] infection,44,45 and race) were available for most of the
patients. Thus, we separately fit models that adjusted for these covariates in prespecified
subgroup analyses, treating patients with unknown status as a separate covariate group.
Proportional-hazards assumptions were assessed graphically with the use of the methods of
Grambsch and Therneau.46 A two-sided P value of 0.05 or less was considered to indicate
statistical significance.
Since patients did not undergo randomization and data censoring was not performed in a
random fashion, we used inverse-probability weighting methods.26,47 To investigate the
sensitivity of our results to potential unmeasured confounding factors associated with the
time to death and deferral of therapy,48 we conducted a set of Monte Carlo simulations49
(for details on both methods, see the Supplementary Appendix, available with the full text of
this article at NEJM.org).
Results
Patients
In the first analysis, 8362 patients (who contributed 23,977 person-years of follow-up) met
the inclusion criteria with a CD4+ count of 351 to 500 cells per cubic millimeter (351-to-500
CD4+ count). Of these patients, 2084 (25%) initiated antiretroviral therapy within 6 months
after the first CD4+ count was within the range of interest, as compared with the remaining
6278 patients (75%), who deferred therapy until the CD4+ cell count fell below the range
(Table 1). Of the patients in the deferred-therapy group, 2829 (45%) were not observed with
a CD4+ count of 350 cells or less per millimeter; data from 22% of the patients were
censored because the patients initiated antiretroviral therapy beyond the 6-month target
window after the first CD4+ count ranged from 351 to 500 cells per millimeter. The other
3449 patients (55%) transitioned to a CD4+ count of 350 cells or less per cubic millimeter;
of these patients, 803 initiated antiretroviral therapy within 6 months after the first CD4+
count of 350 cells or less per cubic millimeter.
In the second analysis, 9155 patients (who contributed 26,439 person-years of follow-up)
met the inclusion criteria with a CD4+ count of more than 500 cells per cubic millimeter
(more-than-500 CD4+ count). Of these patients, 2220 (24%) initiated antiretroviral therapy
within 6 months after the first CD4+ count was within the range of interest, as compared
with the remaining 6935 patients (76%) who deferred therapy. Of the patients in the
deferred-therapy group, 3054 (44%) were not observed with a CD4+ count of 500 cells or
less per millimeter. The other 3881 patients transitioned to a CD4+ count below the
threshold of interest. Of these patients, 539 (14%) initiated antiretroviral therapy within 6
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months after the first CD4+ count of 500 cells or less per cubic millimeter. The proportion
of patients who initiated antiretroviral therapy at a CD4+ count of more than 500 cells per
cubic millimeter peaked at 15% in 1999 and had dropped to less than 10% by 2003.
Demographic and clinical characteristics of the patients in the two groups are shown in
Table 2. In each of the groups with the two thresholds of CD4+ counts, patients in the early-
therapy group were slightly older and were more likely to be white men. At study entry, the
CD4+ count within each of the two ranges of interest was similar in the early-therapy group
and the deferred-therapy group. Among patients with a 351-to-500 CD4+ count, the median
count per cubic millimeter was 422 cells in the early-therapy group and 431 cells in the
deferred-therapy group; among patients with a more-than-500 CD4+ count, the median
count per cubic millimeter was 679 cells in the early-therapy group and 664 cells in the
deferred-therapy group.
In the subgroup of patients for whom data were available, fewer patients with a history of
injection-drug use and HCV infection were in the early-therapy group. Patients in the early-
therapy group were more likely to initiate a protease inhibitor–based regimen that did not
include a ritonavir boost; in the early-therapy group and the deferred-therapy group, the
proportions of patients who initiated a protease inhibitor–based regimen with a ritonavir
boost were low. The proportions of patients who had an HIV RNA level of less than 500
copies per milliliter within 12 months after the initiation of antiretroviral therapy were
clinically similar in the two groups, although among patients with a more-than-500 CD4+
count, there was a statistically significant difference.
Overall Risk of Death
Among patients with a 351-to-500 CD4+ count, there were 137 deaths in the early-therapy
group and 238 deaths in the deferred-therapy group. The crude rate of death for patients in
the early-therapy group was 1.6 deaths per 100 person-years. Among patients with a more-
than-500 CD4+ count, there were 113 deaths in the early-therapy group and 198 deaths in
the deferred-therapy group. The crude rate of death for patients in the early-therapy group
was 1.3 deaths per 100 person-years. A crude rate of death could not be calculated for the
deferred-therapy group because of data censoring to address “outside of protocol”
violations.
The median time until data censoring was 3.7 years (interquartile range, 1.1 to 5.3) in the
early-therapy group and 1.3 years (interquartile range, 0.7 to 2.9) in the deferred-therapy
group among patients with a 351-to-500 CD4+ count and 3.7 years (interquartile range, 1.9
to 5.8) in the early-therapy group and 1.7 years (interquartile range, 0.9 to 3.5) in the
deferred-therapy group among patients with a more-than-500 CD4+ count. At the end of the
study, data on the cause of death had been obtained for 16% of the patients who had died.
The majority of deaths in the early-therapy group and the deferred-therapy group were from
non–AIDS-defining conditions, including hepatic, renal, and cardiovascular diseases and
non–AIDS-defining cancers in both analyses.
351-to-500 CD4+ Count
Among patients with a baseline CD4+ count of 351 to 500 cells per cubic millimeter, the
relative risk of death for deferred therapy, as compared with early therapy, was 1.69 (95%
confidence interval [CI], 1.26 to 2.26; P<0.001), as calculated with weighted Cox regression
analysis stratified according to cohort of patients and the year of the first CD4+ count of 351
to 500 cells per cubic millimeter (Table 3). An increased risk of death was associated with
an older age at baseline (relative risk, 1.68 for each 10-year increment; 95% CI, 1.48 to 1.91;
P<0.001) but not with the patient's sex or the baseline CD4+ count (Table 3). These results
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remained significant and of similar magnitude when data from each of the cohorts were
systematically excluded. Graphical and statistical tests did not suggest any deviation from
the proportionality assumption of any variable except for age. The results in the deferred-
therapy group remained similar after adjustment for age with the use of a cubic regression
spline. There were no significant interactions between the effect of deferred therapy and age,
sex, baseline HIV RNA level, a history of injection-drug use, HCV infection, cohort, or
calendar year; the latter was examined as a continuous or categorical variable.
Some patients had a first CD4+ count of 351 to 500 cells per cubic millimeter in years
before the routine availability of HIV RNA testing. When the analysis was restricted to
patients for whom data were available regarding the baseline HIV RNA level, the relative
risk of death for deferred therapy, as compared with early therapy, was similar to that in the
primary analysis (relative risk, 1.63; 95% CI, 1.21 to 2.19; P = 0.002). However, the HIV
RNA level at baseline was not an independent risk factor for death.
After the exclusion of one group of investigators that did not collect data regarding a history
of injection-drug use and the exclusion of patients with a history of injection-drug use, the
risk of deferred therapy, as compared with early therapy, remained significantly elevated
(relative risk, 1.66; 95% CI, 1.02 to 2.70; P = 0.04). After adjustment for a history of
injection-drug use, the risk of death in the deferred-therapy group was attenuated (relative
risk, 1.28; 95% CI, 0.85 to 1.93; P = 0.23). Patients who had a history of injection-drug use
had a higher risk of death than those with no such history (relative risk, 1.64; 95% CI, 1.10
to 2.44; P = 0.01).
After the exclusion of two groups of investigators that did not collect data regarding HCV
infection, the risk of death in the deferred-therapy group was also similar to that in the
primary analysis (relative risk, 1.71; 95% CI, 1.20 to 2.45; P = 0.003). The presence of HCV
infection was associated with an increased risk of death (relative risk, 1.85; 95% CI, 1.07 to
3.23; P = 0.03). After the exclusion of patients with HCV infection, the risk of death for
deferred therapy remained significantly elevated (relative risk, 1.52; 95% CI, 1.01 to 2.28; P
= 0.04).
Female sex was associated with an increased risk of death in the analysis that included the
HIV RNA level, but the risk was not significant after adjustment for either a history of
injection-drug use or the presence of HCV infection. Race (white vs. all others) was not
significantly associated with an increased risk of death, and the inclusion of race as a
variable in the model did not have an effect on the results. A small proportion of patients in
the deferred-therapy group transitioned to a CD4+ count of less than 200 cells per cubic
millimeter, but the exclusion of these patients from the analysis did not change the results.
More-than-500 Cd4+ Count
Similarly, among patients who had a CD4+ count of more than 500 cells per millimeter, the
risk of death among patients who deferred therapy, as compared with those with early
therapy, increased by 94% (relative risk, 1.94; 95% CI, 1.37 to 2.79; P<0.001). After
restriction of the analysis to patients for whom data on the baseline HIV RNA level were
available, the relative risk for the deferred-therapy group was similar to that in the primary
analysis (relative risk, 1.85; 95% CI, 1.20 to 2.86; P = 0.006).
After the exclusion of one group of investigators that did not collect data regarding a history
of injection-drug use, the risk of death for deferred therapy remained significantly elevated
(relative risk, 1.73; 95% CI, 1.08 to 2.78; P = 0.02). After the exclusion of patients who had
a history of injection-drug use, the risk of death for deferred therapy was of similar
magnitude (relative risk, 2.00; 95% CI, 1.15 to 3.46; P = 0.01). After the exclusion of two
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groups of investigators that did not collect data regarding the status of HCV infection, the
risk of death for deferred therapy was also similar to that in the primary analysis (relative
risk, 2.03; 95% CI, 1.37 to 3.01; P<0.001). After the exclusion of patients with HCV
infection, the risk of death for deferred therapy remained significantly elevated (relative risk,
1.90; 95% CI, 1.14 to 3.18; P = 0.01).
Again, the risk of death was not significantly associated with race or the baseline HIV RNA
level. Female sex was associated with an increased risk of death, but the risk was not
significant after adjustment for the baseline HIV RNA level, a history of injection-drug use,
or the presence of HCV infection. Very few patients in the deferred-therapy group
transitioned to a CD4+ count of less than 350 cells per cubic millimeter. When data from
these patients were censored at the first CD4+ count of less than 350 cells per cubic
millimeter, the relative risk of death among patients in the deferred-therapy group with a
351-to-500 CD4+ count, as compared with patients in the early-therapy group with a more-
than-500 CD4+ count, was 1.80 (95% CI, 1.24 to 2.62; P = 0.002).
Confounding by Unmeasured Covariates
Finally, we evaluated the extent to which an unmeasured covariate might reduce the relative
risk of death. Figure 1 shows the results of the analysis of patients with a 351-to-500 CD4+
count; similar results were seen for the analysis of patients with a more-than-500 CD4+
count. The plot shows that a confounding factor with a relative risk of death of 4.0 and an
odds ratio for the deferral of therapy of 4.0 after adjustment for all included variables would
reduce the estimated relative risk for deferred therapy to approximately 1.30.
Discussion
The results of this study suggest that among patients with a 351-to-500 CD4+ count, the
deferral of antiretroviral therapy was associated with an increase in the risk of death of 69%,
as compared with the early initiation of therapy. Among patients with a more-than-500
CD4+ count, deferred therapy was associated with an increase in the risk of death of 94%.
As has been shown in previous studies, an older age was an independent risk factor for
death,5,50 as were a history of injection-drug use35 and the presence of HCV infection.45
Results regarding the risk of deferred therapy on mortality were robust after adjustment for
these factors and after the exclusion of patients with a history of injection-drug use, who
may have had a higher likelihood of deferring treatment, a poorer level of adherence to
therapy, and a higher risk of death. The type of the initial antiretroviral regimen and the
proportion of patients who achieved viral suppression as a measure of adherence were
clinically similar in the early-therapy group and the deferred-therapy group. The increased
risk of death for patients who deferred treatment was similar throughout the 10-year study
period. The improved rate of survival among patients who initiate antiretroviral therapy at
higher CD4+ counts probably can be attributed to multiple factors, including earlier control
of viral replication and viral diversity and a greater immunologic benefit.34-37 Incomplete
restoration of the CD4+ count is common among patients initiating antiretroviral therapy at
lower CD4+ counts, despite viral suppression for up to 10 years while receiving therapy, and
there may be persistent deficits in immunologic function even with substantial restoration of
the CD4+ count.38,39
Studies in which patients were observed only after they began antiretroviral therapy could
not provide data regarding AIDS events and deaths that occurred during deferral of therapy,
a factor that introduced a lead-time bias.18 Some investigators have applied methods18 to
impute these missing events,21,22,27 using data from patients with HIV infection during the
era before the advent of potent antiretroviral therapy, but such methods may not fully
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address the lead-time bias. In contrast, our study was not subject to such lead-time bias. An
additional strength of our study was the comprehensive ascertainment of mortality through
linkage with national death registries in both the United States and Canada.
The benefits of initiating antiretroviral therapy earlier after HIV infection must be weighed
against potential adverse effects of treatment. Newer antiretroviral therapies that are more
potent, have fewer side effects, and have to be taken less frequently improve adherence and
maintain viral suppression at lower levels of adherence51 than did previous regimens,52
which decreases the risk of drug resistance.53 Furthermore, starting therapy at progressively
higher CD4+ counts has been shown to lower the risk of some toxic effects associated with
antiretroviral therapy, including peripheral neuropathy, anemia, and renal insufficiency.54
However, all the potential side effects of long-term antiretroviral therapy are unknown.
The size and duration of our study enabled us to use death as the end point. This was an
advantage, since death is a more definitive and all-inclusive outcome measure than
progression to an AIDS-defining event, an end point that has been used in previous studies.
Non–AIDS-defining conditions may occur at different rates among patients who defer
therapy, as compared with those who initiate therapy early. HIV infection and decreasing
CD4+ counts are associated with a higher risk of cardiovascular, liver, and renal diseases
and non–AIDS-defining cancers, and treatment with antiretroviral therapy appears to reduce
the risk of these conditions.8,29-33,55,56 Among patients for whom cause-of-death data were
available, the majority of deaths were from causes that were non–AIDS-defining conditions.
There remains uncertainty about when to start antiretroviral therapy for asymptomatic
patients with HIV infection.3,4 Ideally, such data would come from randomized trials.25
Since patients in our study did not undergo randomization, the decision to initiate or defer
antiretroviral therapy could have been influenced by multiple factors. To address potential
confounding, we adjusted the analyses for established risk factors for death in HIV disease
(including age, the CD4+ count, the HIV RNA level, a history of injection-drug use, and the
presence or absence of HCV infection), factors that may also affect the decision to defer
treatment. Patients in the early-therapy group and the deferred-therapy group received
similar initial antiretroviral therapy regimens. In addition, our analyses were adjusted for
potential cohort effects and improvement in survival because of advances in therapies over
time.
Our approach had several limitations. As with any observational study, even after
adjustment for known prognostic factors, residual confounding may occur because of
unmeasured socioeconomic and other factors that may be associated with both deferral of
therapy and death. Whereas only a large, randomized trial can balance such unmeasured
factors, our sensitivity analyses suggest that the effect size of unmeasured confounding
would have to be uncommonly large to mitigate our results. In addition, we made
assumptions in our analyses regarding the target and follow-up windows on the basis of
clinical practice. However, different assumptions might have had an effect on the magnitude
of the relative risk estimates, and such assumptions warrant future study. More careful
assessment of the misclassification inherent in measures of injection-drug use and the
presence of HCV infection will provide a better understanding of how such factors are
associated with a risk of death.
Recommendations for the initiation of therapy for asymptomatic HIV-infected patients have
undergone major shifts since the introduction of potent antiretroviral therapy more than a
decade ago. In 1996, antiretroviral therapy was recommended for all HIV-infected patients
with a CD4+ count of less than 500 cells per cubic millimeter,57 but concern about
resistance,58 inadequate adherence,52 and toxic effects59 led to a shift to delay initiation of
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treatment until later stages of HIV disease. Significant advances in our understanding of the
role of HIV infection in inflammation and immune activation resulting in potentially
irreversible immune-system and end-organ damage have renewed the impetus for earlier
treatment of HIV.60,61
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Figure 1. Results of Sensitivity Analyses Examining the Effect of Possible Unmeasured
Confounding Factors on the Association between Deferral of Antiretroviral Therapy and Death
The contour plot shows that a confounding factor with a relative risk for death of 4.0 and an
odds ratio for deferral of therapy of 4.0 after adjustment for all included variables would
reduce the estimated relative risk for deferred therapy to approximately 1.30.
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Table 1
Stratification of Patients According to CD4+ Count at Baseline.*
Variable 351-to-500 CD4+ Count More-Than-500 CD4+ Count
Patients with a CD4+ count within prespecified range and no history of previous
antiretroviral therapy or AIDS-defining disease — no.
8362 9155
 Patients who initiated antiretroviral therapy within 6 mo — no. 2084 2220
 Patients who deferred antiretroviral therapy — no. 6278 6935
Patients who deferred therapy and who either transitioned to a lower CD4+
count stratum or not
 Transition — no. (no. of cells) 3449 (≤350 cells/mm3) 3881 (≤500 cells/mm3)
 No transition — no. 2829 3054
Timing of initiation of therapy among patients who deferred therapy and who
transitioned to a lower CD4+ count
 Within 6 mo — no. 803 539
 Not within 6 mo — no. 2646 3342
*
The CD4+ count was measured in cells per cubic millimeter.
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Table 2
Characteristics of the Patients, According to the Timing of Initiation of Antiretroviral Therapy and CD4+
Count at Baseline.*
Variable 351-to-500 CD4+ Count More-Than-500 CD4+ Count
Early-Therapy Group Deferred-Therapy Group Early-Therapy Group Deferred-Therapy Group
No. of patients 2084 6,278 2220 6,935
Follow-up person-years (no.) 8353 15,624 8663 17,776
Deaths within 1 yr after last CD4+ count (no.) 137 238 113 198
Age (yr)
 Median 40 38 40 38
 Interquartile range 34–48 32–45 33–48 32–45
Male sex (%) 84 75 82 73
Race (%)†
 White 45 40 49 42
 Black 38 44 36 44
 Other 17 16 15 14
CD4+ count at baseline (cells/mm3)
 Median 422 431 679 664
 Interquartile range 387–460 391–468 580–840 573–811
HIV RNA at baseline (log10 copies/ml)‡
 Median 4.2 4.1 3.5 3.7
 Interquartile range 2.9–4.9 3.4–4.6 2.6–4.6 2.7–4.4
Hepatitis C virus infection (%)§ 27 33 25 35
History of injection-drug use (%)¶ 15 20 14 21
No. of patients who initiated antiretroviral therapy 2084 803 2220 539
Year of initiation of antiretroviral therapy
 Median 2000 2001 2000 2000
 Interquartile range 1998–2001 1998–2003 1998–2001 1998–2003
Interval from first CD4+ count to initiation of
antiretroviral therapy (mo)
 Median 3 3 2 3
 Interquartile range 2–3 2–4 2–3 2–4
CD4+ count at initiation of antiretroviral therapy
(cells/mm3)
 Median 422 286 679 410
 Interquartile range 387–460 228–320 580–840 332–464
Type of first antiretroviral therapy (%)
 Protease inhibitor–based
   Without boost 48 40 50 43
   With boost 9 11 7 9
 Nonnucleoside reverse-transcriptase inhibitor–based 33 38 32 38
 Protease inhibitor and nonnucleoside reverse-
transcriptase inhibitor–based
4 2 4 3
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Variable 351-to-500 CD4+ Count More-Than-500 CD4+ Count
Early-Therapy Group Deferred-Therapy Group Early-Therapy Group Deferred-Therapy Group
 ≥3 Nucleoside reverse-transcriptase inhibitors 6 9 6 8
HIV RNA <500 copies/ml within 12 mo after
initiation of antiretroviral therapy (%)
75 72 81 71
*
The CD4+ count was measured in cells per cubic millimeter. P<0.05 for all comparisons between the early-therapy group and the deferred-
therapy group except for the response to the initiation of antiretroviral therapy in the number of HIV RNA copies in patients with a 351-to-500
CD4+ count (P = 0.16) and the median year of initiation of antiretroviral therapy in patients with a more-than-500 CD4+ count (P = 0.72). HIV
denotes human immunodeficiency virus.
†
Race was self-reported. Race was evaluated in 7657 patients with a CD4+ count of 351 to 500 cells per cubic millimeter and in 8462 patients with
a CD4+ count of more than 500 cells per cubic millimeter.
‡
Baseline HIV RNA levels were evaluated in 6425 patients with a CD4+ count of 351 to 500 cells per cubic millimeter and in 6566 patients with a
CD4+ count of more than 500 cells per cubic millimeter.
§
The status of hepatitis C virus infection was evaluated in 4404 patients with a CD4+ count of 351 to 500 cells per cubic millimeter and in 5147
patients with a CD4+ count of more than 500 cells per cubic millimeter. Data on hepatitis C virus infection were not obtained for two cohorts of
patients.
¶
The status of injection-drug use was evaluated in 5744 patients with a CD4+ count of 351 to 500 cells per cubic millimeter and in 6087 patients
with a CD4+ count of more than 500 cells per cubic millimeter. The use of injection drugs was not evaluated for one cohort.
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Table 3
Risk of Death Associated with Deferral of Antiretroviral Therapy, According to CD4+ Count at Baseline, with
Adjustment for HIV RNA Level, Age, and Sex.*
Variable 351-to-500 CD4+ Count More-Than-500 CD4+ Count
Relative Risk
(95% CI)
P Value Relative Risk
(95% CI)
P Value
Without inclusion of HIV RNA data
 Deferral of antiretroviral therapy 1.69 (1.26–2.26) <0.001 1.94 (1.37–2.79) <0.001
 Female sex 1.21 (0.89–1.64) 0.24 1.85 (1.33–2.59) <0.001
 Older age (per 10-yr increment) 1.68 (1.48–1.91) <0.001 1.83 (1.62–2.06) <0.001
 Baseline CD4+ count (per 100 cells/mm3) 1.13 (0.72–1.78) 0.59 0.93 (0.87–0.99) 0.03
With inclusion of HIV RNA data
 Deferral of antiretroviral therapy 1.63 (1.21–2.19) 0.002 1.85 (1.20–2.86) 0.006
 Female sex 1.47 (1.02–2.12) 0.04 1.35 (0.85–2.15) 0.20
 Older age (per 10-year increment) 1.89 (1.69–2.11) <0.001 1.81 (1.58–2.07) <0.001
 Baseline CD4+ count (per 100 cells/mm3) 0.74 (0.55–1.00) 0.06 0.97 (0.89–1.05) 0.45
 Baseline HIV RNA level (per log10 copies/ml) 1.11 (0.96–1.28) 0.15 1.13 (0.96–1.33) 0.14
*
The CD4+ count was measured in cells per cubic millimeter. Results were calculated with the use of Cox regression analyses with inverse
probability-of-censoring weights. HIV denotes human immunodeficiency virus.
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